雷米马佐拉姆在全身麻醉中对术后恶心和吐的影响:系统性审查和元分析
Su Yeon Kim1, Kyu Man Sim1, Hyo-Seok Na1,2
1Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, 82, Gumiro 173, 13620, Bundang, Seongnam, Gyeonggi, Korea (Republic of).
雷米马佐拉姆是一种新型的二,与普罗波相比,没有增加术后恶心和吐 (PONV) 的风险. 它显著降低了PONV发病率与挥发性药物相比,提高了患者的满意度.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
背景情况:
- 二类药物用于减轻术后恶心和吐 (PONV).
- 存在相互矛盾的证据,关于remimazolam的疗效,一种新型的二,在预防PONV.
研究的目的:
- 为了评估雷米马佐拉姆是否能降低PONV发病率,而不是与普罗波或挥发性麻醉剂相比.
- 评估二次结果,包括PONV严重程度,抗使用和患者满意度.
主要方法:
- 一个11个随机对照试验的元分析,涉及1514名成年患者.
- 在PubMed,EMBASE,CENTRAL和Web of Science数据库中进行系统搜索.
- 用于计算赔率比率和平均差异的随机效应模型;用于偏差评估的Cochrane RoB2工具.
主要成果:
- 雷米马佐拉姆并没有显著改变整体PONV发病率 (16.1%对16.5%).
- 亚组分析显示,雷米马佐拉姆与挥发性物质相比 (OR 0.25) 显著降低了PONV,但与普罗波相比 (OR 1.04) 没有.
- 使用雷米马佐拉姆观察到更高的参与者满意度得分; 雷米芬坦尼尔的使用在比较之间有所不同.
结论:
- 雷米马佐拉姆是安全的选择,与Propofol相比,在PONV风险方面.
- 与挥发性麻醉剂相比,雷米马佐拉姆在减少PONV发病率方面表现出有效性.
- 较高的患者满意度表明,雷米马佐拉姆在临床实践中具有潜在的益处;需要进一步的试验.
更多相关视频
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
相关概念视频
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Parenteral Anesthetics: Overview
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Stages of General Anesthesia
